| Year |
Citation |
Score |
| 2023 |
Im SJ, Obeng RC, Nasti TH, McManus D, Kamphorst AO, Gunisetty S, Prokhnevska N, Carlisle JW, Yu K, Sica GL, Cardozo LE, Gonçalves ANA, Kissick HT, Nakaya HI, Ramalingam SS, et al. Characteristics and anatomic location of PD-1TCF1 stem-like CD8 T cells in chronic viral infection and cancer. Proceedings of the National Academy of Sciences of the United States of America. 120: e2221985120. PMID 37782797 DOI: 10.1073/pnas.2221985120 |
0.323 |
|
| 2023 |
Mani N, Andrews D, Obeng RC. Modulation of T cell function and survival by the tumor microenvironment. Frontiers in Cell and Developmental Biology. 11: 1191774. PMID 37274739 DOI: 10.3389/fcell.2023.1191774 |
0.35 |
|
| 2021 |
Eberhardt CS, Kissick HT, Patel MR, Cardenas MA, Prokhnevska N, Obeng RC, Nasti TH, Griffith CC, Im SJ, Wang X, Shin DM, Carrington M, Chen ZG, Sidney J, Sette A, et al. Functional HPV-specific PD-1 stem-like CD8 T cells in head and neck cancer. Nature. PMID 34471285 DOI: 10.1038/s41586-021-03862-z |
0.357 |
|
| 2021 |
Pinczewski J, Obeng RC, Slingluff CL, Engelhard VH. Phospho-β-catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2. Pathology, Research and Practice. 224: 153527. PMID 34167064 DOI: 10.1016/j.prp.2021.153527 |
0.472 |
|
| 2021 |
Obeng RC, Ambakhutwala AL. Generation of Phosphopeptide-Specific T Cell Lines as Tools for Melanoma Immunotherapy. Methods in Molecular Biology (Clifton, N.J.). 2265: 655-670. PMID 33704746 DOI: 10.1007/978-1-0716-1205-7_45 |
0.503 |
|
| 2020 |
Engelhard VH, Obeng RC, Cummings KL, Petroni GR, Ambakhutwala AL, Chianese-Bullock KA, Smith KT, Lulu A, Varhegyi N, Smolkin ME, Myers P, Mahoney KE, Shabanowitz J, Buettner N, Hall EH, et al. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma. Journal For Immunotherapy of Cancer. 8. PMID 32385144 DOI: 10.1136/Jitc-2019-000262 |
0.574 |
|
| 2014 |
Zarling AL, Obeng RC, Desch AN, Pinczewski J, Cummings KL, Deacon DH, Conaway M, Slingluff CL, Engelhard VH. MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer. Cancer Research. 74: 6784-95. PMID 25297629 DOI: 10.1158/0008-5472.Can-14-0043 |
0.576 |
|
| 2012 |
Zarling AL, Obeng RC, Cummings KL, Desch AN, English AM, Cottine JM, Norris A, Brill LB, Deacon DH, Conaway M, Shabanowitz J, Hunt DF, Slingluff CL, Engelhard VH. Abstract 1584: MHC-restricted phosphopeptides as broad-based immunotherapeutic targets for cancer Cancer Research. 72: 1584-1584. DOI: 10.1158/1538-7445.Am2012-1584 |
0.509 |
|
| 2010 |
Obeng RC, Poole ICL, Hunt DF, Engelhard VH. Abstract B14: A phosphorylated β-catenin peptide that is presented by HLA-A2 MHC molecules generates strong phosphospecific T cell responses against melanoma Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcme10-B14 |
0.57 |
|
| Show low-probability matches. |